Sign up for the premium plan and unlock all options
After purchasing the premium plan, you will unlock all information about drug prices and their availability.
Search
Listing 545801 - 545820 out of 553696 entries
| Country | ATC | Drug name | Drug form, strength, package | Price level | Price in € | Price in local currency | Therapeutic areas | Manufacturer / Importer |
|---|---|---|---|---|---|---|---|---|
| USA | (L01FX09) mogamulizumab | POTELIGEO 4MG/ML INJ,SOLN | 1X5ML | Ex-factory price without vat |
$0-0 |
$0-0 |
Sezary Syndrome;Mycosis Fungoides | KyowaKirin,Inc. |
| USA | (L01FX13) enfortumab vedotin | PADCEV 20MG/VIAL | 1 | Ex-factory price without vat |
$0-0 |
$0-0 |
Carcinoma, Transitional Cell;Urologic Neoplasms | PfizerInc. |
| USA | (L01FX13) enfortumab vedotin | PADCEV 20MG/VIAL | 1 | Ex-factory price without vat |
$0-0 |
$0-0 |
Carcinoma, Transitional Cell;Urologic Neoplasms | PfizerInc. |
| USA | (L01FX13) enfortumab vedotin | PADCEV 30MG/VIAL | 1 | Ex-factory price without vat |
$0-0 |
$0-0 |
Carcinoma, Transitional Cell;Urologic Neoplasms | PfizerInc. |
| USA | (L01FX13) enfortumab vedotin | PADCEV 30MG/VIAL | 1 | Ex-factory price without vat |
$0-0 |
$0-0 |
Carcinoma, Transitional Cell;Urologic Neoplasms | PfizerInc. |
| USA | (L01FX14) polatuzumab vedotin | POLIVY 140MG/VIAL INJ,LYPHL | 1 | Ex-factory price without vat |
$0-0 |
$0-0 |
Lymphoma, B-Cell | GenentechUSA,Inc. |
| USA | (L01FX14) polatuzumab vedotin | POLIVY 140MG/VIAL INJ,LYPHL | 1 | Ex-factory price without vat |
$0-0 |
$0-0 |
Lymphoma, B-Cell | GenentechUSA,Inc. |
| USA | (L01FX14) polatuzumab vedotin | POLIVY 30MG/VIAL INJ,LYPHL | 1 | Ex-factory price without vat |
$0-0 |
$0-0 |
Lymphoma, B-Cell | GenentechUSA,Inc. |
| USA | (L01FX14) polatuzumab vedotin | POLIVY 30MG/VIAL INJ,LYPHL | 1 | Ex-factory price without vat |
$0-0 |
$0-0 |
Lymphoma, B-Cell | GenentechUSA,Inc. |
| USA | (L01FX17) sacituzumab govitecan | TRODELVY | 1 | Ex-factory price without vat |
$0-0 |
$0-0 |
Breast Neoplasms;Triple Negative Breast Neoplasms | GileadSciences,Inc. |
| USA | (L01FX17) sacituzumab govitecan | TRODELVY | 1 | Ex-factory price without vat |
$0-0 |
$0-0 |
Breast Neoplasms;Triple Negative Breast Neoplasms | GileadSciences,Inc. |
| USA | (L01FX18) amivantamab | RYBREVANT 350MG | 7ML | Ex-factory price without vat |
$0-0 |
$0-0 |
Carcinoma, Non-Small-Cell Lung | J&JHealthCareSystemsonbehalfofJanssenBiotechInc. |
| USA | (L01FX18) amivantamab | RYBREVANT 350MG | 7ML | Ex-factory price without vat |
$0-0 |
$0-0 |
Carcinoma, Non-Small-Cell Lung | J&JHealthCareSystemsonbehalfofJanssenBiotechInc. |
| USA | (L01FX20) tremelimumab | IMJUDO 20MG/ML INJ | 1.25ML | Ex-factory price without vat |
$0-0 |
$0-0 |
Carcinoma, Hepatocellular;Carcinoma, Non-Small-Cell Lung | ASTRAZENECAPHARMACEUTICALSLP |
| USA | (L01FX20) tremelimumab | IMJUDO 20MG/ML INJ | 15ML | Ex-factory price without vat |
$0-0 |
$0-0 |
Carcinoma, Hepatocellular;Carcinoma, Non-Small-Cell Lung | ASTRAZENECAPHARMACEUTICALSLP |
| USA | (L01FX20) tremelimumab | IMJUDO 20MG/ML INJ | 1.25ML | Ex-factory price without vat |
$0-0 |
$0-0 |
Carcinoma, Hepatocellular;Carcinoma, Non-Small-Cell Lung | ASTRAZENECAPHARMACEUTICALSLP |
| USA | (L01FX20) tremelimumab | IMJUDO 20MG/ML INJ | 15ML | Ex-factory price without vat |
$0-0 |
$0-0 |
Carcinoma, Hepatocellular;Carcinoma, Non-Small-Cell Lung | ASTRAZENECAPHARMACEUTICALSLP |
| USA | (L01FX22) loncastuximab tesirine | ZYNLONTA 10MG/VIAL INJ | 1 | Ex-factory price without vat |
$0-0 |
$0-0 |
Lymphoma, Large B-Cell, Diffuse;Lymphoma, B-Cell | ADCTherapeuticsAmerica,Inc. |
| USA | (L01FX23) tisotumab vedotin | TIVDAK 40MG VIAL | 1 | Ex-factory price without vat |
$0-0 |
$0-0 |
Uterine Cervical Neoplasms | PfizerInc. |
| USA | (L01FX23) tisotumab vedotin | TIVDAK 40MG VIAL | 1 | Ex-factory price without vat |
$0-0 |
$0-0 |
Uterine Cervical Neoplasms | PfizerInc. |
Pages
